Abstract: The invention provides a human KLK2 which is associated with the hematological disorders, cancer, cardiovascular diseases, inflammatory diseases, neurological disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological disorders, cancer, cardiovascular diseases, inflammatory diseases, neurological disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK2 as well as pharmaceutical compositions comprising such compounds.

Abstract: The present invention is directed to a polynucleotide and polypeptide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X2. The invention also provides the human MGAT-X2 associated with the cardiovascular diseases, metabolic diseases, muscle-skeleton disorders or dermatological diseases. The invention also provides assays for the identification of compounds useful for the modulation of cardiovascular diseases, dermatological diseases, metabolic diseases or muscle-skeleton disorders for treating of cardiovascular diseases, metabolic diseases, muscle-skeleton disorders or dermatological diseases associated with expression of the MGAT-X2. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X2 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human RNPEP which is associated with the cardiovascular diseases, cancer, dermatological diseases, hematological diseases, neurological diseases, urological diseases, respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, dermatological diseases, hematological diseases, neurological diseases, urological diseases, respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of RNPEP as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK8 which is associated with the cardiovascular diseases, dermatological diseases, neurological diseases, metabolic diseases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, neurological diseases, metabolic diseases, cancer disorders, urological diseases, gastroenterological diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK8 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK13 which is associated with the hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, neurological diseases, metabolic diseases, endocrinological diseases, dermatological diseases, gastroenterological diseases, urological diseases, cancer disorders and inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK13 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human NPEPL1 which is associated with the cardiovascular diseases, cancer, dermatological diseases, gastroenterological diseases, metabolic diseases, inflammation, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, dermatological diseases, gastroenterological diseases, metabolic diseases, inflammation, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NPEPL1 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human PDE1A which is associated with the cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, endocrine system and hormone disorders, cancer disorders, gastrointestinal and liver diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1A as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK12 which is associated with the gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of gastrointestinal and liver diseases, cancer disorders, hematological diseases, inflammatory diseases, respiratory diseases, neurological disorders, cardiovascular disorders, reproduction disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK12 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human EDG6 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders, thrombocytopenia and myeloma. The invention also features compounds which bind to and/or activate or inhibit the activity of EDG6 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human 5-HT7 which is associated with the cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT7 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human NAALADASE 2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, neurologcial diseases, urological diseases, respiratory diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, neurological diseases, urological diseases, respiratory diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of NAALADASE 2 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human KLK9 which is associated with the hematological diseases, cardiovascular diseases, neurological diseases, metabolic diseases, urological diseases, cancer disorders, inflammation disorders, dermatological diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, neurological diseases, metabolic diseases, urological diseases, cancer disorders, inflammation disorders, dermatological diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK9 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human GPR85 which is associated with the cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, hematological disorders, inflammatory diseases, metabolic diseases, neurological disorders, urological disorders, respiratory diseases, cancer disorders and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR85 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human 5-HT4 which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, inflammatory diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT4 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human prostaglandin E2 EP1 which is associated with the cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases and metabolic diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, respiratory diseases, hematological diseases, urological diseases, gastrointestinal diseases, endocrinological diseases an and metabolic diseases. The invention also features compounds which hind to and/or activate or inhibit the activity of prostaglandin E2 EP1 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR2 as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human RNPEP-like which is associated with the cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of RNPEP-like as well as pharmaceutical compositions comprising such compounds.

Abstract: The invention provides a human AdipoR1 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR1 as well as pharmaceutical compositions comprising such compounds.

Abstract: The present invention is directed to a polynucleotide sequence of a novel organic anion transporting (OAT)-like protein UST3-like1. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand. The invention also provides the human UST3-LIKE1 associated with the gastrointestinal and liver diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cardiovascular diseases as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling. The invention also provides assays for the identification of compounds useful for the modulation of said diseases.

Abstract: The invention provides a human MSP which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases, urological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases, urological diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of MSP as well as pharmaceutical compositions comprising such compounds.